IMVT · Immunovant, Inc.
AI read · Neutral
The AI's read
The higher estimate suggests Truist sees more possible share-price growth. Keeping its Hold rating tempers that signal. The report adds no new company results or drug updates.
Truist Securities raised its price target for Immunovant to $33.00 a share from $30.00.
Neutral
Truist raised its target from $30 to $33 but kept its Hold rating. The higher target is tempered by the unchanged rating, so the report does not clearly change Immunovant's business prospects.
Get alerts for IMVT
Follow Immunovant, Inc. (IMVT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IMVTFree on the App Store and Google Play, or on the web.